WO2013016720A3 - Novel substituted biarylheterocycle derivatives as protein kinase inhibitors for the treatment of cancer and other diseases - Google Patents
Novel substituted biarylheterocycle derivatives as protein kinase inhibitors for the treatment of cancer and other diseases Download PDFInfo
- Publication number
- WO2013016720A3 WO2013016720A3 PCT/US2012/048741 US2012048741W WO2013016720A3 WO 2013016720 A3 WO2013016720 A3 WO 2013016720A3 US 2012048741 W US2012048741 W US 2012048741W WO 2013016720 A3 WO2013016720 A3 WO 2013016720A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein kinase
- diseases
- biarylheterocycle
- cancer
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Abstract
The present invention provides a new patentable class of substituted benzoxazole derivative compounds that exhibit protein kinase (PK) inhibition activity or modulating ability, as well as compositions and methods of using such compounds, for example, to prevent or treat various diseases and disorders in human and non-human animals.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161512882P | 2011-07-28 | 2011-07-28 | |
US61/512,882 | 2011-07-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2013016720A2 WO2013016720A2 (en) | 2013-01-31 |
WO2013016720A3 true WO2013016720A3 (en) | 2013-03-28 |
Family
ID=47601783
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2012/048741 WO2013016720A2 (en) | 2011-07-28 | 2012-07-28 | Novel substituted biarylheterocycle derivatives as protein kinase inhibitors for the treatment of cancer and other diseases |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2013016720A2 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CR20170098A (en) | 2010-05-20 | 2017-07-17 | Array Biopharma Inc | MACROCICLICAL COMPOUNDS AS QUINASA TRK INHIBITORS |
MX2018000577A (en) | 2015-07-16 | 2018-09-05 | Array Biopharma Inc | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors. |
JOP20190077A1 (en) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
TWI704148B (en) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
EP3571203B1 (en) | 2017-01-18 | 2023-06-07 | Array BioPharma Inc. | Substituted pyrazolo[1,5-a]pyrazine compounds as ret kinase inhibitors |
WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
JOP20190213A1 (en) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | Macrocyclic compounds as ros1 kinase inhibitors |
TWI812649B (en) | 2017-10-10 | 2023-08-21 | 美商絡速藥業公司 | Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile |
TWI791053B (en) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | Crystalline forms of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile and pharmaceutical composition thereof |
CN111971286B (en) | 2018-01-18 | 2023-04-14 | 阿雷生物药品公司 | Substituted pyrrolo [2,3-d ] pyrimidine compounds as RET kinase inhibitors |
JP7061195B2 (en) | 2018-01-18 | 2022-04-27 | アレイ バイオファーマ インコーポレイテッド | Substituted pyrazolo [3,4-d] pyrimidine compound as a RET kinase inhibitor |
US11472802B2 (en) | 2018-01-18 | 2022-10-18 | Array Biopharma Inc. | Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors |
WO2020055672A1 (en) | 2018-09-10 | 2020-03-19 | Array Biopharma Inc. | Fused heterocyclic compounds as ret kinase inhibitors |
CN116253686B (en) * | 2022-12-09 | 2023-11-17 | 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) | Aminobenzimidazole benzamide derivative and application thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2262932C2 (en) * | 2000-12-15 | 2005-10-27 | Вертекс Фармасьютикалз Инкорпорейтед | Inhibitors of bacterial gyrase and their applying |
WO2009156966A1 (en) * | 2008-06-25 | 2009-12-30 | Ranbaxy Laboratories Limited | Benzothiazoles and aza-analogues thereof use as antibacterial agents |
-
2012
- 2012-07-28 WO PCT/US2012/048741 patent/WO2013016720A2/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2262932C2 (en) * | 2000-12-15 | 2005-10-27 | Вертекс Фармасьютикалз Инкорпорейтед | Inhibitors of bacterial gyrase and their applying |
WO2009156966A1 (en) * | 2008-06-25 | 2009-12-30 | Ranbaxy Laboratories Limited | Benzothiazoles and aza-analogues thereof use as antibacterial agents |
Also Published As
Publication number | Publication date |
---|---|
WO2013016720A2 (en) | 2013-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2013016720A3 (en) | Novel substituted biarylheterocycle derivatives as protein kinase inhibitors for the treatment of cancer and other diseases | |
MX2014005928A (en) | Heterocyclic inhibitors of glutaminase. | |
TN2013000348A1 (en) | Compounds and compositions as trk inhibitors | |
EA201791018A1 (en) | DERIVATIVES OF 6-AMINO-7-BICYCLO-7-DEAZAPURIN AS PROTECTINININASE INHIBITORS | |
EA201490545A1 (en) | COMPOUNDS AND COMPOSITIONS AS KINASE C-Kit KINASE INHIBITORS | |
MY167245A (en) | Compounds and compositions as c-kit kinase inhibitors | |
TN2012000081A1 (en) | Compounds and compositions as protein kinase inhibitors | |
WO2014031928A3 (en) | Heterocyclic modulators of hif activity for treatment of disease | |
WO2011014795A3 (en) | Compounds and compositions as syk kinase inhibitors | |
MX2009011951A (en) | Compounds and compositions as c-kit and pdgfr kinase inhibitors. | |
MX2013012981A (en) | Substituted indazole derivatives active as kinase inhibitors. | |
EA201490542A1 (en) | COMPOUNDS AND COMPOSITIONS AS A PDGFR KINASE INHIBITOR | |
MX2010009207A (en) | Heterocyclic compounds and compositions as c-kit and pdgfr kinase inhibitors. | |
EA201290191A1 (en) | N1-PYRAZOLOSPIROKETONE INHIBITORS ACETYL-KoA-CARBOXYLASE | |
EA201500182A1 (en) | 4-METHYL-2,3,5,9,9b-PENTAASACYCLOPENT [a] NAFTAIL | |
WO2014031933A3 (en) | Heterocyclic modulators of hif activity for treatment of disease | |
IN2015DN01151A (en) | ||
WO2014031936A3 (en) | Heterocyclic modulators of hif activity for treatment of disease | |
EA201490539A1 (en) | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | |
EA201390520A1 (en) | SUBSTITUTED COMPOUNDS PYRIDAZINCARBOXAMIDA | |
MX2009011952A (en) | Compounds and compositions as c-kit and pdgfr kinase inhibitors. | |
MX337849B (en) | Compositions and methods for inhibition of the jak pathway. | |
MY167898A (en) | Co-crystals and salts of ccr3-inhibitors | |
EP2563794A4 (en) | Inhibitors of protein tyrosine kinase activity and use thereof to treat ophthalmic disorders | |
WO2012103282A3 (en) | Methods and compositions for treating alzheimer's disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12818072 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 12818072 Country of ref document: EP Kind code of ref document: A2 |